Kairos Pharma is a clinical stage biopharmaceutical company at the forefront of cancer treatment innovation. Led by the Clinical Chief of Neurosurgery and Director of Surgical Neuro-Oncology at Cedars Sinai Medical Center, our mission is to harness immunity against cancer and drug resistance, revolutionizing patient outcomes and quality of life in the process. We are uniquely positioned to achieve this goal through our diversified pipeline of novel drug development.

Our pipeline includes peptide and small molecule cancer immunotherapeutics, such as KROS-101, 102, 201, 301, and 401, as well as therapeutic agents ENV105 and ENV205 for drug resistance. At Kairos Pharma, we have a world-class team with a proven track record in drug development, commercialization, and multiple successful M&A exits. We have licensed proprietary technologies from Cedars-Sinai Medical Center, a leading academic medical center, to further advance our development efforts.

With a disciplined focus on intellectual property and exclusive worldwide patent licenses, we are targeting a high-value market in the fast-growing $311 billion drug industry. Join us on our journey to advance immunotherapy and transform cancer treatment. Stay informed by connecting with us through our website and social media platforms.

Together, we can make a difference in the fight against cancer